janssen_latest_logo_on_sign

NICE recommends Janssen’s Darzalex myeloma combo

pharmafile | March 12, 2019 | News story | Manufacturing and Production Janssen, NICE, Velcade, darzalex, myeloma 

Britain’s cost effectiveness body NICE have recommended Janssen Pharmaceutical’s Darzalex in combination with Velcade and dexamethasone (DVd), for use within the cancer drugs fund as an option for treating relapsed multiple myeloma in people who have had one previous treatment.

In recommending the treatment NICE agreed that the drug combo was “clinically important and statistically significant effect on progression-free survival.” However the government body stopped short of making the treatment routinely available as they argued that data to back up its survival benefit in the long-term is limited.

The drug will be offered through the Cancer Drugs Fund and will thus be available to patients. However Janssen commented in suggesting it was disappointed that routine access was not being offered on the NHS.

Advertisement

Jennifer Lee, director of health economics, market access and reimbursement (HEMAR) and advocacy at Janssen, commented: “While it is positive news that patients will now be able to access DVd, it is disappointing that NICE – despite recognising the life-extending, step-change this combination represents for patients – did not recommend routine access on the NHS. The parameters through which NICE determines uncertainty need urgent re-evaluation.”

Louis Goss

Related Content

Digital mental health technologies – a valuable tool in supporting people with depression and anxiety

The potential benefits of digital mental health technology for managing depression, anxiety and stress, together …

Combination treatments: Takeda’s Implementation Framework and the broader landscape

Pharmafile talks to Emma Roffe, Oncology Country Head (UK & Ireland) about the combination treatment …

blood-1813410_960_720

FDA grants orphan drug designation to relapsed or refractory multiple myeloma candidate

The US Food and Drug Administration (FDA) has granted orphan drug designation to SAR446523, Sanofi’s …

The Gateway to Local Adoption Series

Latest content